Cargando…
Control of mammary tumor differentiation by SKI-606 (bosutinib)
C-Src is infrequently mutated in human cancers but it mediates oncogenic signals of many activated growth factor receptors and thus remains a key target for cancer therapy. However, the broad function of Src in many cell types and processes requires evaluation of Src-targeted therapeutics within a n...
Autores principales: | Hebbard, Lionel, Cecena, Grace, Golas, Jonathon, Sawada, Junko, Ellies, Lesley G., Charbono, Adriana, Williams, Roy, Jimenez, Rebecca E., Wankell, Miriam, Arndt, Kim T., DeJoy, Susan Q., Rollins, Robert A., Diesl, Veronica, Follettie, Maxmillian, Chen, Lei, Rosfjord, Edward, Cardiff, Robert D., Komatsu, Masanobu, Boschelli, Frank, Oshima, Robert G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000443/ https://www.ncbi.nlm.nih.gov/pubmed/20818417 http://dx.doi.org/10.1038/onc.2010.412 |
Ejemplares similares
-
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015) -
Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRI(ca)Col1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)
por: Wermuth, Peter J., et al.
Publicado: (2018) -
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576
Publicado: (2013) -
Preparation 606
Publicado: (1910) -
Syphilis and "606."
Publicado: (1910)